AMP Capital Investors’s Neurocrine Biosciences NBIX Stock Holding History

AMP Capital Investors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-18,032	Closed	-$1.73M	–	712
2021 Q3	$1.73M	Sell	18,032 -1,484	-8%	-$140K	0.01%	759
2021 Q2	$1.9M	Sell	19,516 -12,495	-39%	-$1.2M	0.01%	757
2021 Q1	$3.1M	Buy	32,011 +12,076	+61%	+$1.27M	0.02%	707
2020 Q4	$1.9M	Buy	19,935 +362	+2%	+$35K	0.01%	760
2020 Q3	$1.91M	Buy	19,573 +2,550	+15%	+$295K	0.01%	726
2020 Q2	$2.14M	Buy	17,023 +2,993	+21%	+$331K	0.01%	685
2020 Q1	$1.28M	Hold	14,030	–	–	0.01%	734
2019 Q4	$1.5M	Buy	+14,030	New	+$1.47M	0.01%	802
2014 Q1	–	Sell	-17,497	Closed	-$165K	–	1236
2013 Q4	$165K	Hold	17,497	–	–	﹤0.01%	1193
2013 Q3	$200K	Buy	+17,497	New	+$241K	﹤0.01%	1141

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AMP Capital Investors's NBIX Position: Q4 2021 in Review

AMP Capital Investors sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 18,032 shares — an estimated $1.73M sold.

AMP Capital Investors first reported a position in NBIX in Q3 2013 and held it in 10 quarters. The position peaked at $3.1M in Q1 2021. 406 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

AMP Capital Investors reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
AMP Capital Investors sold 18,032 Neurocrine Biosciences shares in Q4 2021, an estimated $1.73M.
AMP Capital Investors first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 10 quarters.
AMP Capital Investors's Neurocrine Biosciences position peaked at $3.1M in Q1 2021.
406 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on AMP Capital Investors's 13F filing for Q4 2021, filed 14 Feb 2022.